asset acquisition
Novo Nordisk Scoops up 2seventy's Hemophilia A Program, Gene Editing Technology
The deal, which is worth up to $40 million, will allow 2seventy to maintain its focus on advancing the multiple myeloma CAR T-cell therapy Abecma.
Laboratoires Théa Acquires Two Ophthalmic RNA Drugs From ProQR Therapeutics
The divestiture will allow ProQR to develop other pipeline products, including treatments for cholestatic diseases and its RNA-editing technology.
Quest Adds to Cancer Portfolio With $450M Buy of Haystack Oncology; Q1 Revenues Down 11 Percent
Premium
The firm said the acquisition let it move into the "fast growing" MRD space and round out its offerings in cancer screening, pathology, and sequencing.
Meilleur Technologies Buys Rights to Navidea's Beta-Amyloid Imaging Agent
The $750,000 asset purchase agreement gives Meilleur the exclusive license to develop and commercialize NAV4694 for diagnosing Alzheimer's disease.
NEC OncoImmunity Acquires Vaximm's Neoantigen Vaccine Program
The firm expects to begin clinical trials of personalized cancer vaccines based on Vaximm's assets this year.